# SMLR1

## Overview
SMLR1 is a gene that encodes the small leucine-rich protein 1, which is categorized as a membrane-associated protein involved in lipid metabolism. This protein is predominantly expressed in the liver and plays a crucial role in the regulation of very low-density lipoprotein (VLDL) secretion, a process essential for maintaining lipid homeostasis and preventing hepatic lipid accumulation (van2024VLDL). The small leucine-rich protein 1 is located in the endoplasmic reticulum (ER) membrane and the cis-Golgi, indicating its involvement in the transport of VLDL from the ER to the Golgi apparatus (van2024VLDL). Alterations in the expression of SMLR1 have been linked to metabolic disorders such as Metabolic Associated Fatty Liver Disease (MAFLD) and have potential implications in oncogenesis, making it a significant focus of research in both metabolic and cancer biology (Masood2023Genetic; Fu2024Examining).

## Function
SMLR1 (small leucine-rich protein 1) is primarily expressed in the liver, where it plays a significant role in the regulation of very low-density lipoprotein (VLDL) secretion. It is located in the endoplasmic reticulum (ER) membrane and the cis-Golgi, suggesting its involvement in the transport of VLDL from the ER to the Golgi apparatus (van2024VLDL). The protein is implicated in the regulation of VLDL transport vesicles in primary hepatocytes, which is crucial for maintaining lipid homeostasis and preventing hepatic lipid accumulation (van2024VLDL; Fu2024Examining).

The loss of SMLR1 in mice has been shown to result in a significant reduction in VLDL secretion and an increase in hepatic triglyceride levels, leading to hepatic steatosis (van2024VLDL). This indicates that SMLR1 is essential for the proper assembly and secretion of VLDL, which is vital for preventing excessive triglyceride and cholesterol accumulation that can contribute to metabolic-associated fatty liver disease (MAFLD) (Fu2024Examining). Despite its recognized role in VLDL metabolism, the exact molecular mechanisms by which SMLR1 functions in these processes are not yet fully understood (van2024VLDL).

## Clinical Significance
The SMLR1 gene, encoding the small leucine-rich protein 1, has been implicated in several metabolic and potentially oncogenic processes. Alterations in SMLR1 expression are associated with hepatic lipid metabolism disorders. Specifically, the loss of hepatic SMLR1 in mice leads to hepatic steatosis and a significant reduction in very-low-density lipoprotein (VLDL) secretion, suggesting a role in conditions like Metabolic Associated Fatty Liver Disease (MAFLD) (van2024VLDL; Fu2024Examining). The deficiency of SMLR1 results in a 45% reduction in VLDL secretion and a sevenfold increase in hepatic triglyceride levels, indicating its critical role in maintaining lipid homeostasis (van2024VLDL).

In addition to its metabolic implications, SMLR1 has been identified as a potential anticancer gene. Genetic screening has revealed that SMLR1 can induce cell death in certain cancer cell lines, highlighting its potential as a novel anticancer target (Masood2023Genetic). While specific diseases directly linked to SMLR1 mutations are not extensively documented, its involvement in lipid metabolism and cancer cell death suggests significant clinical relevance in these areas. Further research is needed to fully elucidate the molecular mechanisms and potential therapeutic applications of SMLR1.


## References


[1. (Fu2024Examining) Yansong Fu, Zhipeng Wang, and Hong Qin. Examining the pathogenesis of mafld and the medicinal properties of natural products from a metabolic perspective. Metabolites, 14(4):218, April 2024. URL: http://dx.doi.org/10.3390/metabo14040218, doi:10.3390/metabo14040218. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/metabo14040218)

[2. (van2024VLDL) Willemien van Zwol, Bart van de Sluis, Henry N. Ginsberg, and Jan Albert Kuivenhoven. Vldl biogenesis and secretion: it takes a village. Circulation Research, 134(2):226–244, January 2024. URL: http://dx.doi.org/10.1161/circresaha.123.323284, doi:10.1161/circresaha.123.323284. This article has 7 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1161/circresaha.123.323284)

[3. (Masood2023Genetic) Motasim Masood, Qize Ding, Adam D. Cawte, David S. Rueda, Stefan W. Grimm, Ernesto Yagüe, and Mona El-Bahrawy. Genetic screening for anticancer genes highlights fbln5 as a synthetic lethal partner of myc. Cell Communication and Signaling, October 2023. URL: http://dx.doi.org/10.1186/s12964-023-01300-3, doi:10.1186/s12964-023-01300-3. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12964-023-01300-3)